Sustiva, empowered by its chief component, Efavirenz, stands as a cornerstone in the lineup of antiretroviral medications, distinctly classifying itself within the non-nucleoside reverse transcriptase inhibitors (NNRTIs). This class of drugs has carved a niche for itself, having played a pivotal role in revolutionizing HIV care for countless individuals worldwide.